Increased levels of anti-glycan antibodies in patients with cystic fibrosis

Table 1 Comparison of demographic and serological parameters used in this study

Parameter	CF (n = 119)	CD (n = 34)	UC (n = 11)	RA (n = 22)	HC (n = 16)	p < 0.05
Gender (m/f)	67/52	14/20	3/8	5/17	10/6	n.s.
Age	23.0	36.5	30.0	57.5	29.0	RA vs. all
(years)	[16, 33]*	[29, 58]	[25, 61]	[49, 64]	[28, 34]
WBC	8.9	8.5	8.5	8.0	n.d.	n.s.
(/nl)	[7, 11]	[5, 10]	[6, 11]	[6, 11]
CRP	0.3	0.4	0.3	0.3	n.d.	n.s.
(mg/dl)	[0.1, 1.0]	[0.1, 1.2]	[0.05, 1,0]	[0.1, 3.9]
ALCA	18.8	30.8	16.3	14.3	23.3	CD vs. RA
(U/ml)	[12, 32]	[21, 50]	[12, 29]	[9, 20]	[19, 31]
ACCA	22.2	35.4	30	24.1	35.6	n.s.
(U/ml)	[17, 39]	[22, 47]	[16, 40]	[17, 31]	[27, 42]
AMCA	29.9	32.8	23.1	23.8	30.6	n.s.
(U/ml)	[23, 46]	[25, 55]	[16, 26]	[20, 30]	[20, 40]
gASCA	55.6	88.9	20.5	20.0	23.0	CD vs.
(U/ml)	[27, 124]	[51, 14.3]	[15, 40]	[14, 27]	[10, 38]	CU, RA, HC

Continuous variables: median [Q25%, Q75%], WBC = white blood cell count; CRP = C-reactive protein; CF = cystic fibrosis; CD = Crohn's disease; UC = ulcerative colitis; RA = rheumatoid arthritis; HC = healthy volunteers. Differences between groups were compared by ANOVA with Scheffe-Test or Fisher's exact test(*) with Bonferroni.

ISSN: 2047-783X